Brilacidin, a COVID‐19 drug candidate, demonstrates broad‐spectrum antiviral activity against human coronaviruses OC43, 229E, and NL63 through targeting both the virus and the host cell

Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies

(2021) Dami A. Collier et al.   NATURE

Brilacidin Demonstrates Inhibition of SARS-CoV-2 in Cell Culture

(2021) Allison Bakovic et al.   Viruses-Basel

Boceprevir, Calpain Inhibitors II and XII, and GC-376 Have Broad-Spectrum Antiviral Activity against Coronaviruses

(2021) Yanmei Hu et al.   ACS Infectious Diseases

Inflammation, immunity and potential target therapy of SARS-COV-2: A total scale analysis review

(2021) Shukur Wasman Smail et al.   FOOD AND CHEMICAL TOXICOLOGY

Expedited Approach toward the Rational Design of Noncovalent SARS-CoV-2 Main Protease Inhibitors

(2021) Naoya Kitamura et al.   JOURNAL OF MEDICINAL CHEMISTRY

SARS-CoV-2 evolution and vaccines: cause for concern?

(2021) Thomas C Williams et al.   Lancet Respiratory Medicine

Discovery of Potent and Broad-Spectrum Pyrazolopyridine-Containing Antivirals against Enteroviruses D68, A71, and Coxsackievirus B3 by Targeting the Viral 2C Protein

(2021) Yanmei Hu et al.   JOURNAL OF MEDICINAL CHEMISTRY

Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant

(2021) Jamie Lopez Bernal et al.   NEW ENGLAND JOURNAL OF MEDICINE

Strategies to target SARS-CoV-2 entry and infection using dual mechanisms of inhibition by acidification inhibitors

(2021) Chaitra Prabhakara et al.   PLoS Pathogens

Rapid, reliable, and reproducible cell fusion assay to quantify SARS-Cov-2 spike interaction with hACE2

(2021) Min Zhao et al.   PLoS Pathogens

Heparan Sulfate Proteoglycans as Attachment Factor for SARS-CoV-2

(2021) Lin Liu et al.   ACS Central Science

The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health — The latest 2019 novel coronavirus outbreak in Wuhan, China

(2020) David S. Hui et al.   INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES

Triple artemisinin-based combination therapies versus artemisinin-based combination therapies for uncomplicated Plasmodium falciparum malaria: a multicentre, open-label, randomised clinical trial

(2020) Rob W van der Pluijm et al.   LANCET

Analysis of the susceptibility of lung cancer patients to SARS-CoV-2 infection

(2020) Qi Kong et al.   Molecular Cancer

Cell entry mechanisms of SARS-CoV-2

(2020) Jian Shang et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Protocol and Reagents for Pseudotyping Lentiviral Particles with SARS-CoV-2 Spike Protein for Neutralization Assays

(2020) Katharine H. D. Crawford et al.   Viruses-Basel

Development of broad-spectrum enterovirus antivirals based on quinoline scaffold

(2020) Rami Musharrafieh et al.   BIOORGANIC CHEMISTRY

Boceprevir, GC-376, and calpain inhibitors II, XII inhibit SARS-CoV-2 viral replication by targeting the viral main protease

(2020) Chunlong Ma et al.   CELL RESEARCH

The value of antimicrobial peptides in the age of resistance

(2020) Maria Magana et al.   LANCET INFECTIOUS DISEASES

Pharmacological Characterization of the Mechanism of Action of R523062, a Promising Antiviral for Enterovirus D68

(2020) Chunlong Ma et al.   ACS Infectious Diseases

Characterization of heparin and severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) spike glycoprotein binding interactions

(2020) So Young Kim et al.   ANTIVIRAL RESEARCH

SARS-CoV-2 Infection Depends on Cellular Heparan Sulfate and ACE2

(2020) Thomas Mandel Clausen et al.   CELL

Heparin-binding Peptides as Novel Therapies to Stop SARS-CoV-2 Cellular Entry and Infection

(2020) Omid Tavassoly et al.   MOLECULAR PHARMACOLOGY

From Antimicrobial to Anticancer Peptides: The Transformation of Peptides

(2019) Yuan Qin et al.   Recent Patents on Anti-Cancer Drug Discovery

Membrane protein of HCoV-NL63 is responsible for interaction with the adhesion receptor.

(2019) Antonina Naskalska et al.   JOURNAL OF VIROLOGY

The Antimicrobial Peptide Database provides a platform for decoding the design principles of naturally occurring antimicrobial peptides

(2019) Guangshun Wang   PROTEIN SCIENCE

Human Antimicrobial Peptides as Therapeutics for Viral Infections

(2019) Aslaa Ahmed et al.   Viruses-Basel

Heparan Sulfate Proteoglycans and Viral Attachment: True Receptors or Adaptation Bias?

(2019) Cagno et al.   Viruses-Basel

A novel druggable interprotomer pocket in the capsid of rhino- and enteroviruses

(2019) Rana Abdelnabi et al.   PLOS BIOLOGY

A Novel Capsid Binding Inhibitor Displays Potent Antiviral Activity against Enterovirus D68

(2019) Chunlong Ma et al.   ACS Infectious Diseases

Discovery of Influenza Polymerase PA–PB1 Interaction Inhibitors Using an In Vitro Split-Luciferase Complementation-Based Assay

(2019) Jiantao Zhang et al.   ACS Chemical Biology

Chemical Genomics Approach Leads to the Identification of Hesperadin, an Aurora B Kinase Inhibitor, as a Broad-Spectrum Influenza Antiviral

(2017) Yanmei Hu et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Combination therapy in combating cancer

(2017) Reza Bayat Mokhtari et al.   Oncotarget

Mimics of Host Defense Proteins; Strategies for Translation to Therapeutic Applications

(2016) Richard W. Scott et al.   CURRENT TOPICS IN MEDICINAL CHEMISTRY

An Independent Evaluation of a Novel Peptide Mimetic, Brilacidin (PMX30063), for Ocular Anti-Infective

(2016) Regis P. Kowalski et al.   JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS

Middle East respiratory syndrome

(2015) Alimuddin Zumla et al.   LANCET

Comparative Mechanistic Studies of Brilacidin, Daptomycin, and the Antimicrobial Peptide LL16

(2014) Bruk Mensa et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Human Coronavirus NL63 Utilizes Heparan Sulfate Proteoglycans for Attachment to Target Cells

(2014) A. Milewska et al.   JOURNAL OF VIROLOGY

A Human Coronavirus Responsible for the Common Cold Massively Kills Dendritic Cells but Not Monocytes

(2012) M. Mesel-Lemoine et al.   JOURNAL OF VIROLOGY